GHRP-6

What it is

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide made up of six amino acids. It was one of the first compounds developed to trigger the pituitary gland into releasing growth hormone. Cyril Bowers and Frank Momany created it in the early 1980s while researching how to stimulate GH secretion without using growth hormone releasing hormone (GHRH) itself. (Bowers et al., Endocrinology, 1984. PMID: 6432247)

GHRP-6 belongs to the class of growth hormone secretagogues (GHSs). These are compounds that act on the ghrelin receptor (GHS-R1a) in the pituitary gland to release stored growth hormone in a pulsatile pattern. What sets GHRP-6 apart from newer secretagogues like Ipamorelin is its potent appetite stimulation. For some users, this is the main reason to choose it. For others, it's the main reason to avoid it.

The peptide has been studied for over 40 years. PubMed lists more than 640 publications involving GHRP-6, covering everything from GH release in healthy volunteers to cardioprotective effects in animal models. Despite this long research history, GHRP-6 has never received FDA approval for any indication.

How it works

GHRP-6 binds to the growth hormone secretagogue receptor type 1a (GHS-R1a) on cells in the anterior pituitary gland. This triggers a calcium signaling cascade inside those cells, which causes them to release stored growth hormone into the bloodstream. The GH pulse typically peaks within 15 to 30 minutes after injection. (Locatelli et al., Pediatric Research, 1994. PMID: 7970930)

The GHS-R1a receptor is the same one that ghrelin, the body's natural hunger hormone, activates. This is why GHRP-6 produces such strong appetite stimulation. It is not just a side effect. It is a direct result of the peptide hitting the same receptor that tells your brain you need to eat. The hunger typically kicks in within 20 minutes of injection and lasts about an hour.

GHRP-6 also works at the hypothalamic level by amplifying GHRH signaling and suppressing somatostatin, the hormone that puts the brakes on GH release. This dual action at both the pituitary and hypothalamus makes GHRP-6 a stronger overall GH stimulator than compounds that only work at one site. However, it comes with a tradeoff: GHRP-6 also raises cortisol and prolactin levels, something that Ipamorelin does not do.

Once growth hormone enters the bloodstream, it stimulates the liver to produce insulin-like growth factor 1 (IGF-1). IGF-1 drives most of the downstream effects people care about: fat metabolism, protein synthesis, tissue repair, and recovery from training.

What the research shows

Human studies confirm that GHRP-6 produces reliable, dose-dependent growth hormone release. In a study of 10 healthy men, a single intravenous bolus of 1 mcg/kg of GHRP-6 increased peak GH levels by an average of 10-fold above baseline within 15 minutes. (Arvat et al., Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9024244)

The appetite stimulation effect is well documented. A study comparing GHRP-6 to GHRP-2 and Ipamorelin found that GHRP-6 produced the strongest increase in food intake among all three peptides, with caloric intake rising by roughly 30% in the hours following administration. GHRP-2 produced moderate appetite effects, and Ipamorelin produced almost none. This makes GHRP-6 specifically useful for people who struggle to eat enough, whether due to illness, age, or simply having a small appetite while trying to gain muscle.

Sleep studies show mixed but interesting results. Researchers found that repeated GHRP-6 administration increased the amount of stage 2 sleep and elevated nocturnal GH, ACTH, and cortisol levels compared to placebo. (Frieboes et al., Journal of Neuroendocrinology, 1999. PMID: 10336729) The cortisol elevation is worth noting because it separates GHRP-6 from more selective peptides like Ipamorelin.

Beyond growth hormone release, GHRP-6 has shown cardioprotective properties in animal models. A 2024 study demonstrated that GHRP-6 prevented heart damage caused by doxorubicin (a chemotherapy drug) in rats, reducing fibrosis and preserving cardiac function. (Wang et al., Pharmaceuticals, 2026. PMID: 41901314) These protective effects appear to work through pathways independent of GH release, suggesting GHRP-6 has biological activity beyond its primary secretagogue role.

The evidence is stronger in animals than in humans. Most human data comes from acute dosing studies measuring GH release, not long-term trials measuring body composition outcomes. This is a real limitation. People extrapolate from the GH numbers, but controlled trials showing GHRP-6 specifically builds muscle or burns fat in humans over weeks or months are scarce.

Typical protocol

Standard dosing ranges from 100 to 300 mcg per injection, administered subcutaneously 2 to 3 times per day. Most community protocols settle on 100 mcg as a starting dose to assess tolerance, then move to 200 to 300 mcg based on response. Higher doses do not produce proportionally more GH release once the receptor is saturated.

Timing matters more with GHRP-6 than with most peptides because of its appetite effects. The most common schedule is an injection upon waking (fasted), another mid-afternoon, and a third before bed. The pre-bed dose tends to work well because the hunger wave passes during sleep, and nocturnal GH release gets a significant boost. Food should be avoided for at least 30 minutes before and after injection, as elevated blood sugar and insulin blunt the GH response.

For people who want to maximize GH output, stacking GHRP-6 with a GHRH analog like CJC-1295 (without DAC) is a common approach. The GHRP triggers the pulse, and the GHRH amplifies it. This combination typically produces a larger GH spike than either compound alone.

Reconstitution follows standard peptide protocols: add 2 ml of bacteriostatic water to a 5 mg vial to create a 2.5 mg/ml solution. For a 200 mcg dose, draw 0.08 ml (8 units on an insulin syringe). Refrigerate after mixing. Most reconstituted peptide solutions remain stable for 4 to 6 weeks when kept cold. Use the peptide calculator for exact measurements at different concentrations.

Cycle length is typically 8 to 12 weeks followed by a 4-week break. Desensitization of the GHS-R1a receptor is a concern with longer continuous use, though the evidence for this in humans at standard doses is limited.

Note: These protocols reflect commonly reported usage patterns from published research and community experience, not medical prescriptions. Individual responses vary based on age, body composition, and health status.

Side effects and risks

The most obvious side effect is intense hunger. Unlike the mild appetite bump from some secretagogues, GHRP-6 can produce a strong, almost uncomfortable urge to eat within 20 minutes of injection. For people trying to lose weight, this is a real problem. For people trying to bulk, it can be a useful tool.

GHRP-6 raises cortisol and prolactin levels, which is its biggest pharmacological downside compared to Ipamorelin. Cortisol is a stress hormone that promotes fat storage and muscle breakdown when chronically elevated. Prolactin elevation can cause mood changes, water retention, and in rare cases, gynecomastia (breast tissue growth in men). These effects are generally mild at standard doses but become more significant with higher doses or prolonged use.

Water retention is more common with GHRP-6 than with Ipamorelin, likely driven by the cortisol and prolactin effects. Some users notice puffiness in the face and hands, especially during the first two weeks. This usually subsides as the body adjusts.

Injection site reactions are common but mild: redness, itching, or a small welt that fades within an hour. Numbness or tingling in the hands (similar to carpal tunnel symptoms) can occur with any compound that raises GH levels significantly, as GH promotes fluid retention in soft tissues.

Contraindications include active cancer (GH and IGF-1 can accelerate tumor growth), diabetes (GH affects insulin sensitivity), and pregnancy or breastfeeding. Anyone with a history of prolactin-sensitive conditions should consider a more selective peptide like Ipamorelin instead. Consult a healthcare provider before starting any protocol.

Related compounds